Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999-2001

被引:20
作者
Harris, Norma S. [1 ]
Fowler, Mary Glenn
Sansom, Stephanie L.
Ruffo, Nan
Lampe, Margaret A.
机构
[1] Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA USA
[2] CDC Informat Technol Support, Atlanta, GA USA
关键词
antiretroviral; HIV/AIDS; perinatal; surveillance;
D O I
10.1016/j.ajog.2007.03.081
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: Significant reductions in perinatal human immunodeficiency virus (HIV) transmission have been demonstrated in which the HIV-infected mothers and their HIV-exposed infants receive prenatal, intrapartum, and neonatal antiretroviral therapy. STUDY DESIGN: We used data that were collected through the Enhanced Perinatal Surveillance system for HIV-exposed singleton births that occurred 1999-2001 in 24 sites. RESULTS: The overall infant infection rate for the 3 years was 4.7%. Compared with zidovudine monotherapy, those patients who received zidovudine with other drugs that included a protease inhibitor and those who received zidovudine and other drugs with no protease inhibitor were less likely to have an infected infant (adjusted odds ratio, 0.4 [95% CI, 0.3-0.07]; adjusted odds ratio, 0.5 [95% CI, 0.3-0.8], respectively). CONCLUSION: These data support the current treatment recommendations and show that infants were less likely to be infected when the mothers were given a prenatal antiretroviral therapy regimen that contained zidovudine with additional antiretroviral drugs with or without a protease inhibitor in addition to receiving antiretrovirals during delivery and neonatally.
引用
收藏
页码:S33 / S41
页数:9
相关论文
共 30 条
  • [1] Dooley Samuel W., 2008, Morbidity and Mortality Weekly Report, V57, P1
  • [2] Basedow T, 2002, Z PFLANZENK PFLANZEN, V109, P1
  • [3] *CDCP, 2004, MMWR-MORBID MORTAL W, V48, P1
  • [4] *CDCP, 2001, MMWR RECOMM REP, V50, P63
  • [5] *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P329
  • [6] Centers for Disease Control and Prevention, 2001, HIV AIDS SURVEILLANC, V13, P1
  • [7] REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT
    CONNOR, EM
    SPERLING, RS
    GELBER, R
    KISELEV, P
    SCOTT, G
    OSULLIVAN, MJ
    VANDYKE, R
    BEY, M
    SHEARER, W
    JACOBSON, RL
    JIMENEZ, E
    ONEILL, E
    BAZIN, B
    DELFRAISSY, JF
    CULNANE, M
    COOMBS, R
    ELKINS, M
    MOYE, J
    STRATTON, P
    BALSLEY, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) : 1173 - 1180
  • [8] COOPER E, 1996, C RETROVIRUSES OPPOR, V3, P57
  • [9] After AIDS clinical trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants
    Cooper, ER
    Nugent, RP
    Diaz, C
    Pitt, J
    Hanson, C
    Kalish, LA
    Mendez, H
    Zorrilla, C
    Hershow, R
    Moye, J
    Smeriglio, V
    Fowler, MG
    Rich, K
    Turpin, D
    PachecoAcosta, E
    Tuomala, R
    Mesthene, D
    Fox, H
    Higgins, A
    Landesman, S
    Moroso, G
    Willoughby, A
    Sheon, A
    McKinlay, S
    Sherrieb, K
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) : 1207 - 1211
  • [10] COOPER ER, 2004, J ACQ IMMUN DEF SYND, V29, P484